Biomaterial Database

Delayed-type hypersensitivity against Semliki Forest virus in mice. 1979

C A Kraaijeveld, and M Harmsen, and B Khader Boutahar-Trouw

After intracutaneous immunization with purified inactivated Semliki Forest virus, a delayed-type hypersensitivity without detectable antibodies in serum was obtained in BALB/c mice. Low doses of antigen given intraperitoneally induced antibodies. Intracutaneous immunization with much higher doses induced no specific antibodies, but a footpad swelling was observed after challenge with homolgous antigen. Pretreatment with cyclophosphamide before immunization enhanced footpad swelling. Microscopic examination of footpads from sensitized mice at 24 h after challenge showed a mononuclear infiltrate. The delayed-type reaction could be transferred to syngenic mice with lymph node cells, but not with spleen cells or serum. The biphasic character of the delayed-type hypersensitivity is discussed.

UI	MeSH Term	Description	Entries
D006968	Hypersensitivity, Delayed	An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS.	Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007114	Immunization	Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).	Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007116	Immunization, Passive	Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).	Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D008198	Lymph Nodes	They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.	Lymph Node,Node, Lymph,Nodes, Lymph
D008297	Male		Males
D008807	Mice, Inbred BALB C	An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research.	BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D003520	Cyclophosphamide	Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.	(+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D000914	Antibodies, Viral	Immunoglobulins produced in response to VIRAL ANTIGENS.	Viral Antibodies
D000956	Antigens, Viral	Substances elaborated by viruses that have antigenic activity.	Viral Antigen,Viral Antigens,Antigen, Viral

Related Publications

C A Kraaijeveld, and M Harmsen, and B Khader Boutahar-Trouw

Delayed-type hypersensitivity in mice after infection with avirulent Semliki Forest virus. Brief report.

January 1983, Archives of virology,

C A Kraaijeveld, and M Harmsen, and B Khader Boutahar-Trouw

Delayed onset of encephalitis in mice passively immunised against Semliki Forest virus.

August 1971, British journal of experimental pathology,

C A Kraaijeveld, and M Harmsen, and B Khader Boutahar-Trouw

Antiviral agents from fungi effective against Semliki Forest virus (SFV) in mice.

September 1973, The Indian journal of medical research,

C A Kraaijeveld, and M Harmsen, and B Khader Boutahar-Trouw

Delayed multiplication of Semliki forest virus in organ cultures of muscle from vaccinated mice.

November 1976, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie,

C A Kraaijeveld, and M Harmsen, and B Khader Boutahar-Trouw

A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.

November 1992, Immunology,

C A Kraaijeveld, and M Harmsen, and B Khader Boutahar-Trouw

Prevention of death in Semliki Forest virus-infected mice by administration of defective-interfering Semliki Forest virus.

May 1978, The Journal of general virology,

C A Kraaijeveld, and M Harmsen, and B Khader Boutahar-Trouw

Neurogenic spread of Semliki Forest virus in mice.

January 1987, Archives of virology,

C A Kraaijeveld, and M Harmsen, and B Khader Boutahar-Trouw

Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.

February 1999, Vaccine,